|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Oxidative Desulfurization over Molybdenum-containing MCM-41显示文摘包含铝的 MCM-41 催化剂的二个系列作为 oxidant.The 用 t-butylhydroperoxide ( TBHP )为 dibenzothiophene ( DBT )的氧化 desulfurization 作好准备电子性质,毛孔尺寸和催化剂的吸水的性质被 XRD 学习,赌注,并且红外 spectrometry.The Mo-Al2O3 催化剂和TiMCM-3%也为 comparison.The 被学习有在框架的 MoO3 的 MCM-41 沸石的二个系列或在低 MoO3 conten | Xu Li Zhang Wenhao Fan Heli Xie Chaogang Wang Danhong Peng Zhien Wang Xieqing | 2009 | China Petroleum Processing & Petrochemical Technology2009，11，3： | 1 |
| 2 | MEN1 promotes ferroptosis by inhibiting mTOR-SCD1 axis in pancreatic neuroendocrine tumors显示文摘Pancreatic neuroendocrine tumor(pNET)is the second most common malignant tumors of the pancreas.Multiple endocrine neoplasia 1(MEN1)is the most frequently mutated gene in pNETs and MEN1-encoded protein,menin,is a scaffold protein that interacts with transcription factors and chromatin-modifying proteins to regulate various signaling pathways.However,the role of MEN1 in lipid metabolism has not been studied in pNETs.In this study,we perform targeted metabolomics analysis and find that MEN1 promotes the generation and oxidation of polyunsaturated fat acids(PUFAs).Meanwhile lipid peroxidation is a hallmark of ferroptosis,and we confirm that MEN1 promotes ferroptosis by inhibiting the activation of mTOR signaling which is the central hub of metabolism.We show that stearoyl-coA desaturase(SCD1)is the downstream of MEN1-mTOR signaling and oleic acid(OA),a metabolite of SCD1,recues the lipid peroxidation caused by MEN1 overexpression.The negative correlation between MEN1 and SCD1 is further verified in clinical specimens.Furthermore,we find that BON-1 and QGP-1 cells with MEN1 overexpression are more sensitive to everolimus,a widely used drug in pNETs that targets mTOR signaling.In addition,combined use everolimus with ferroptosis inducer,RSL3,possesses a more powerful ability to kill cells,which may provide a new strategy for the comprehensive therapy of pNETs. | Zeng Ye Haidi Chen Shunrong Ji Yuheng Hu Xin Lou Wuhu Zhang Desheng Jing Guixiong Fan Yue Zhang Xuemin Chen Qifeng Zhuo Jie Chen Xiaowu Xu Xianjun Yu Jin Xu Yi Qin Heli Gao | 2022 | Acta Biochimica et Biophysica Sinica2022，54，11： | 0 |
| 3 | Double-tract reconstruction is superior to esophagogastrostomy in controlling reflux esophagitis and enhancing quality of life after proximal gastrectomy:Results from a prospective randomized controlled clinical trial in China显示文摘Objective:The aim of this study was to prospectively compare double-tract reconstruction(DTR)and esophagogastrostomy(EG)after proximal gastrectomy(PG)regarding the incidence of reflux esophagitis,quality of life(QOL),nutritional status and surgical safety.Methods:This study was a randomized controlled trial.Patients eligible for PG were enrolled and randomly assigned to the EG group and DTR group.The characteristics of patients,parameters for surgical safety,incidence of reflux esophagitis,nutrition status and QOL were collected and compared between the two groups.Univariate analysis and multivariate analysis were performed to determine the significant factors affecting the incidence of reflux esophagitis after PG.Results:Thirty-seven patients of the EG group and 36 patients of the DTR group were enrolled.The incidence of reflux esophagitis was significantly lower in the DTR group than in the EG group(8.3%vs.32.4%,P=0.019).The DTR group demonstrated a more favorable QOL than the EG group after PG.The nutritional status was balanced within the EG group and the DTR group.The operation time was longer in the DTR group than in the EG group(191 min vs.221 min,P=0.001),while surgical safety was similar in the two groups.Conclusions:Our research demonstrated that DTR is superior to EG after PG in terms of the incidence of reflux esophagitis and provides a more satisfactory QOL without increasing surgical complications or sacrificing nutritional status. | Yinan Zhang Hongtao Zhang Yan Yan Ke Ji Ziyu Jia Heli Yang Biao Fan Anqiang Wang Xiaojiang Wu Ji Zhang Jiafu Ji Xin Ji Zhaode Bu | 2023 | Chinese Journal of Cancer Research2023，35，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员